Growth Trends in the $483 Million Tele-epilepsy Market, 2024-2035: Eyes $2.46 Billion Valuation by 2035 with Wearable Devices and Remote Monitoring Revolutionizing the Industry
14 janv. 2025 04h17 HE
|
Research and Markets
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "Tele-epilepsy Market by Epilepsy Type, Patient Type, Component, End User and Region" report has been added to ResearchAndMarkets.com's offering. This...
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment
13 janv. 2025 09h00 HE
|
NeuroSigma, Inc.
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology & Neuroscience is a multicentre, double-blind,...
Coave Therapeutics lève €32 millions d'euros en série A pour accélérer le développement de ses médicaments génétiques de nouvelle génération
09 janv. 2025 03h00 HE
|
Coave Therapeutics
Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...
Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines
09 janv. 2025 03h00 HE
|
Coave Therapeutics
Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...
Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease
08 janv. 2025 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Clinical Trial Outsourcing Market Expected To Reach USD 111.01 Billion by 2032, Growing at a CAGR of 8.7% From 2024-2032 | Introspective Market Research
19 déc. 2024 06h27 HE
|
Introspective Market Research
United Kingdom, London, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Australian healthcare technology company Resonance Health completed the acquisition of 100% of clinical research center TrialsWest for a...
New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
11 déc. 2024 09h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the Center for Evidence-Based Psychiatry (CEBP) in Denmark has...
Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-Resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
06 déc. 2024 12h00 HE
|
Neurona Therapeutics
Neurona Therapeutics Presents Positive Clinical Update:
New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meet
Technetium-99m Market Poised for Growth, Projected to Reach Over US$ 8.6 Billion by 2034 | Transparency Market Research
28 nov. 2024 09h30 HE
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research, Inc., Nov. 28, 2024 (GLOBE NEWSWIRE) -- The Technetium-99m market (Marché du technétium-99m) is experiencing significant growth due to its...
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care
21 nov. 2024 09h00 HE
|
DANNCE.AI
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform.